- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02341508
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
May 4, 2016 updated by: Lpath, Inc.
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab Administered Intravenously to Healthy Volunteers
The primary purpose of this study is to evaluate the safety and tolerability of Lpathomab in healthy volunteers.
Additional endpoints include characterization of the pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity profiles of a single IV dose of Lpathomab in healthy volunteers.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- PRA Health Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Healthy male or female subject ≥ 18 years old between 50 and 145 kg
- Laboratory values and ECG during Screening period within normal range or evaluated as not clinically significant (NCS)
- Female subjects must be not of child-bearing potential or using double-barrier method of contraception
- Male subjects must use double-barrier contraception during the study period
- Subject is able to read, understand, and sign the informed consent form (ICF) and HIPAA release
Key Exclusion Criteria:
- Subjects with diabetes mellitus (glycated hemoglobin [HbA1c]≥6.5%) or pre-diabetes mellitus (HbA1c between 5.7 and 6.4%).
- Male subjects with corrected Q-T interval (QTc)> 450 msec or a QRS interval>120 msec and female subjects with QTc> 470 or a QRS interval>120 msec.
- Subject's blood pressure (BP) during screening period exceeds 140/90 mm Hg
- Subject is positive for HIV, hep B and/or hep C at screening
- Subject has significant psychiatric co-morbidity including but not limited to major depression-severe, bipolar disorder or schizophrenia spectrum disorder, history of suicide attempt, or active suicidal ideation in 6 months prior to screen.
- Subject has any significant or advanced systemic illness, unstable or severe medical condition(s) or end stage disease that could put them at risk during the study, interfere with outcome measures, or affect compliance with the protocol procedures and requirements.
- Subject has history of cancer stability/remission for less than 5 years, with the exception of non-metastatic basal and/or squamous cell carcinomas of the skin and cervical cancer in situ.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lpathomab
0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab,
|
|
Placebo Comparator: Placebo
Saline solution for intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with local or systemic Adverse Events
Time Frame: 85 days
|
85 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Dario A Paggiarino, MD, Lpath, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
January 7, 2015
First Submitted That Met QC Criteria
January 13, 2015
First Posted (Estimate)
January 19, 2015
Study Record Updates
Last Update Posted (Estimate)
May 6, 2016
Last Update Submitted That Met QC Criteria
May 4, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- LT3114-NPP-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruiting
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Vigonvita Life SciencesRecruiting
Clinical Trials on 0.5 mg/kg Lpathomab
-
Atox Bio LtdTerminatedAcute Kidney Injury | Peritonitis | Necrotizing Soft Tissue InfectionUnited States, France
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Terminated
-
PfizerCompletedAlzheimer's DiseaseKorea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
-
JANSSEN Alzheimer Immunotherapy Research & Development...PfizerCompletedAlzheimer's DiseaseUnited States, Germany, Canada, Austria
-
JANSSEN Alzheimer Immunotherapy Research & Development...PfizerCompletedAlzheimer's DiseaseUnited States
-
Regado Biosciences, Inc.CompletedHealthy VolunteerUnited States
-
Atox Bio LtdBiomedical Advanced Research and Development AuthorityCompletedNecrotizing Fasciitis | Necrotizing Soft Tissue Infections | Fournier's GangreneUnited States, France
-
University of ReadingCompletedVasodilationUnited Kingdom
-
PfizerTerminatedAlzheimer DiseaseAustralia, France, Finland, Portugal, Spain, United Kingdom, Poland, Japan, Italy, Belgium, Switzerland, Netherlands, Chile, Slovakia, Sweden, New Zealand, South Africa
-
Cardiox CorporationWithdrawn